Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report

The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Int Med Res
Autores principales: Cai, Yangyang, Wang, Yizhuo, Sun, Jingnan, Wang, Xu, Xu, Yinghui, Sun, Chao, Guo, Ye, Sun, Mengyao, Ma, Kewei
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7273558/
https://ncbi.nlm.nih.gov/pubmed/32493093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060520928793
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares